Home Page

The role of an implantable Doppler vascular monitoring device in kidney transplant patients: a feasibility randomised controlled trial with an embedded qualitative study (CONDOR Study)

CONDOR study

The role of an implantable Doppler vascular monitoring device in kidney transplant patients: a feasibility randomised controlled trial with an embedded qualitative study (CONDOR Study)

Kidney transplantation is the most effective and safest treatment of end-stage renal disease (ESRD) and while there is an 87% chance of five year survival, complications do occur. 10% of kidneys are lost within the first three months due to early graft loss (EGL) which accounts for 20% of patients currently on the national kidney transplant waiting list. EGL is a devastating outcome that can result in cardiovascular complications, infections, physiological stress due to returning to haemodialysis and mortality.Cook-swartz implantable doppler flow probe a. with silicon cuff b. connected to monitoring device

One way to increase the life expectancy of both the kidney and recipient is to diagnose vascular complications earlier, allowing corrective surgery to take place sooner. As part of a PhD with the University of Plymouth and with support from the Southwest Transplant Centre, Mr Shahzar Malik, Associate Specialist in Transplantation has developed a research study in collaboration with Professor Jos Latour, Professor in Clinical Nursing and Mr Somaiah Aroori, Consultant Hepatobiliary and Transplant Surgeon to determine whether a continuous monitoring device, with an implantable Doppler probe can improve postoperative outcomes in patients receiving a kidney transplant. The device is currently used successfully in plastic and breast reconstructive surgery, and allows the blood flow of grafted tissues to be monitored by producing audible Doppler signals. It is thought that using this device for the first 72 hours following kidney transplantation may identify vascular complications sooner, when compared to routine clinical observation.

Over two years, fifty participants will be randomly allocated to receive a transplanted kidney with a continuous monitoring device alongside routine clinical observation, or receive a transplanted kidney with routine clinical observation only. Twelve members of staff and participants directly involved with the device will also be invited to take part in an interview exploring their experiences and views. The results will determine whether a larger definitive trial can be conducted which will have an aim of testing if the device can be used in the care of kidney transplant recipients in the future.

Was this page helpful?

Was this page helpful?
Rating

Please answer the question below, this helps us to reduce the number of spam emails that we receive so that we can spend more time responding to genuine enquiries and feedback. Thank you.

*

Our site uses cookies to help give you a better experience. If you choose not to accept these cookies, our site will still work correctly but some content may not display. You can read our cookie policy here

Please choose a setting: